01/09/2014 22:16:59 Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
08/06/20144:02PMPRNUSNeurocrine Biosciences Reports Second Quarter 2014 Results
Neurocrine Biosciences Reports Second Quarter 2014 Results SUCCESSFUL END-OF-PHASE II MEETING FOR NBI-98854 IN TARDIVE DYSKINESIA TOURETTE SYNDROME IND FOR NBI-98854 TO BE FILED THIS MONTH PR Newswire SAN DIEGO, Aug. 6, 2014 SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced... More...>>
07/29/201410:00AMPRNUSNeurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results Earnings Release After Close of Market, Wednesday, August 6, 2014 Conference Call and Webcast Scheduled For Thursday, August 7, 2014 PR Newswire SAN DIEGO, July 29, 2014 SAN DIEGO, July 29, 2014 /PRNewswire/ -- Neurocrine... More...>>
06/11/20147:00AMPRNUSNeurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Diso...
Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress DATA FROM KINECT 1 AND KINECT 2 TARDIVE DYSKINESIA STUDIES PR Newswire SAN DIEGO, June 11, 2014 SAN DIEGO, June 11, 2014 /PRNewswire/ -- Neurocrine Biosciences... More...>>
05/29/20141:00PMPRNUSNeurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference
Neurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference Live Audio Webcast will be on June 5, 2014 PR Newswire SAN DIEGO, May 29, 2014 SAN DIEGO, May 29, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
05/08/20141:00PMPRNUSNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference Live Audio Webcast will be on May 15, 2014 PR Newswire SAN DIEGO, May 8, 2014 SAN DIEGO, May 8, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
05/01/20141:00PMPRNUSNeurocrine Biosciences to Present at Deutsche Bank's 39th Annual Health Care Conference
Neurocrine Biosciences to Present at Deutsche Bank's 39th Annual Health Care Conference Live Audio Webcast will be on May 8, 2014 PR Newswire SAN DIEGO, May 1, 2014 SAN DIEGO, May 1, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
04/30/20144:01PMPRNUSNeurocrine Biosciences Reports First Quarter 2014 Results
Neurocrine Biosciences Reports First Quarter 2014 Results -Endometriosis Phase III Violet Petal Study Completes Screening- -Tardive Dyskinesia Phase III Initiation Planned for Second Half of 2014- -Over $270 Million to Fund Clinical Pipeline- PR Newswire SAN DIEGO, April 30, 2014 SAN DIEGO, April 30, 2014 /PRNewswire/... More...>>
04/25/20143:30PMPRNUSNeurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial Results
Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial Results Conference Call and Webcast Scheduled For Wednesday, April 30, 2014 PR Newswire SAN DIEGO, April 25, 2014 SAN DIEGO, April 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>>
04/14/20148:00AMPRNUSHealthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Ce...
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, April 14, 2014 NEW YORK... More...>>
04/10/201412:30PMPRNUSBiotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, April 10, 2014 LONDON, April 10, 2014 /PRNewswire/ -- On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90... More...>>
03/04/20142:00PMPRNUSNeurocrine Biosciences To Present At The 26th Annual Roth Conference
Neurocrine Biosciences To Present At The 26th Annual Roth Conference Live Audio Webcast will be on March 11, 2014 PR Newswire SAN DIEGO, March 4, 2014 SAN DIEGO, March 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine... More...>>
02/27/20147:00PMPRNUSNeurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference Live Audio Webcast will be on March 4, 2014 PR Newswire SAN DIEGO, Feb. 27, 2014 SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
02/26/20149:12PMPRNUSNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock PR Newswire SAN DIEGO, Feb. 26, 2014 SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public... More...>>
02/25/20144:00PMPRNUSNeurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, Feb. 25, 2014 SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. ... More...>>
02/25/20147:30AMPRNUSNeurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Soci...
Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED PR Newswire SAN DIEGO, Feb. 25, 2014 SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX... More...>>
02/07/201410:00AMPRNUSNeurocrine Biosciences To Present At The Leerink Global Healthcare Conference
Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference Live Audio Webcast will be on February 12, 2014 PR Newswire SAN DIEGO, Feb. 7, 2014 SAN DIEGO, Feb. 7, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine... More...>>
02/06/20144:01PMPRNUSNeurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results
Neurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results PROVIDES UPDATE ON RAPIDLY ADVANCING PIPELINE AND FINANCIAL GUIDANCE FOR 2014 PR Newswire SAN DIEGO, Feb. 6, 2014 SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter... More...>>
02/04/20149:20AMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results Conference Call and Webcast Scheduled For Thursday, February 6, 2014 PR Newswire SAN DIEGO, Feb. 4, 2014 SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced... More...>>
01/09/20144:31PMPRNUSNeurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING PR Newswire SAN DIEGO, Jan. 9, 2014 SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:... More...>>
01/07/20149:17AMDJNU.S. Hot Stock Futures: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Tuesday's session are Cyan Inc. (CYNI), Neurocrine Biosciences Inc. (NBIX) and SandRidge Energy Inc. (SD). Shares of Cyan slumped 25% to $3.86 premarket after the company drastically cut its fourth-quarter revenue expectations due to a sharp drop in orders from... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nbix140901 22:17